OMTH Omthera Pharmaceuticals, Inc. (MM)

The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Omthera Pharmaceuticals, Inc. (“Omthera” or the “Company”) (Nasdaq: OMTH) and other violations of state law by the board of directors of Omthera relating to the proposed buyout of the Company by AstraZeneca PLC. The firm’s investigation seeks to determine, among other things, whether the board of directors of Omthera breached their fiduciary duties by failing to maximize shareholder value.

According to the press release announcing the proposed buyout, Omthera shareholders will receive $12.70 per share in cash for each share of Omthera common stock they own. In addition to the cash payment, each Omthera stockholder will receive one Contingent Value Right of up to approximately $4.70 for each share they own, equating to $120 million, if specified milestones related to Epanova are achieved, or if a milestone related to global net sales is achieved.

If you currently own common stock of Omthera and would like to learn more about the investigation being conducted by Brower Piven, you may email or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at hoffman@browerpiven.com, by calling (410) 415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and other class action cases of over 60 years.

OMTHERA PHARMACEUTICALS, INC. (NASDAQ:OMTH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

OMTHERA PHARMACEUTICALS, INC. (NASDAQ:OMTH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024